Shares of Corcept Therapeutics Inc. (CORT) are up over 85% at $101.48 today, following encouraging data from its phase III trial of Relacorilant in patients with platinum-resistant ovarian cancer, dubbed ROSELLA.
In the ROSELLA trial, the enrolled 381 patients with platinum-resistant ovarian cancer, were randomized 1:1 to receive either Relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.